Business Description
Corvus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US2210151005
Total Employee Number:
37Description
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 283.83 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 8 | |||||
3-Year EPS without NRI Growth Rate | 0.8 | |||||
3-Year FCF Growth Rate | 11 | |||||
3-Year Book Growth Rate | -12.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -54.46 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.02 | |||||
9-Day RSI | 74.33 | |||||
14-Day RSI | 65.84 | |||||
3-1 Month Momentum % | -16.89 | |||||
6-1 Month Momentum % | 54.83 | |||||
12-1 Month Momentum % | 205.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.81 | |||||
Quick Ratio | 19.81 | |||||
Cash Ratio | 19.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.1 | |||||
Shareholder Yield % | -14.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -43.89 | |||||
ROA % | -39.89 | |||||
ROIC % | -303.67 | |||||
3-Year ROIIC % | 80.74 | |||||
ROC (Joel Greenblatt) % | -4159.52 | |||||
ROCE % | -47.33 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.33 | |||||
Price-to-Tangible-Book | 5.33 | |||||
EV-to-EBIT | -21.85 | |||||
EV-to-EBITDA | -21.9 | |||||
EV-to-FCF | -29.81 | |||||
| Price-to-Net-Current-Asset-Value | 5.64 | |||||
| Price-to-Net-Cash | 5.72 | |||||
Earnings Yield (Greenblatt) % | -4.58 | |||||
FCF Yield % | -2.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Corvus Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.447 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 181.95 | ||
| 14-Day RSI | 65.84 | ||
| 14-Day ATR (€) | 0.533906 | ||
| 20-Day SMA (€) | 10.90545 | ||
| 12-1 Month Momentum % | 205.38 | ||
| 52-Week Range (€) | 3.195 - 21.7 | ||
| Shares Outstanding (Mil) | 84.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corvus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corvus Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 33 days | ||
| General meeting for 2025 | 2026-06-11 13:00 | 9.92 (+7.06%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 11:20 | 9.69 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:45 | 9.74 (+0.00%) | ||
| Corvus SID Investor & Analyst Meeting | 2026-05-14 13:30 | 13.21 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 13.37 (+2.81%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-12 16:30 | 14.06 (+0.00%) |
Show
Entries
Corvus Pharmaceuticals Inc Frequently Asked Questions
What is Corvus Pharmaceuticals Inc(FRA:C17)'s stock price today?
The current price of FRA:C17 is €13.26. The 52 week high of FRA:C17 is €21.70 and 52 week low is €3.20.
When is next earnings date of Corvus Pharmaceuticals Inc(FRA:C17)?
The next earnings date of Corvus Pharmaceuticals Inc(FRA:C17) is 2026-08-07 Est..
Does Corvus Pharmaceuticals Inc(FRA:C17) pay dividends? If so, how much?
Corvus Pharmaceuticals Inc(FRA:C17) does not pay dividend.
Press Release
Articles on Corvus Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers